PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD
In this contemporary population of statin-treated patients with type 2 diabetes and hypertriglyceridemia, 1 in 10 developed a cardiovascular event by 3 years, and despite 20-30% reductions of triglycerides and what we call remnant cholesterol with a fibrate-like therapy, there was no clinical benefit.
In this interview, Aruna Das Pradhan MD, MPH and Allen J. Taylor MD, FACC discuss PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD.
- Pradhan et al, NEJM "Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk" - November 5th, 2022
Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Hypertriglyceridemia
Keywords: ACCELLite, Hypertriglyceridemia
< Back to Listings